Kytril (Granisetron)

Granisetron works by selectively blocking serotonin (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. By preventing serotonin from binding to these receptors, it stops the neural signals that trigger the vomiting centre, thereby reducing nausea and vomiting.

The dose of Kytril is determined by the prescribing clinician based on the patient’s specific clinical situation, such as the type of chemotherapy or the surgical procedure. Dosage regimens are individualized and should follow the prescriber’s instructions and local guidelines.

Safety of Granisetron in pregnancy and lactation has not been fully established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Kytril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Kytril (Granisetron) and other 5‑HT3 antagonists such as ondansetron share the same mechanism of blocking serotonin receptors. Granisetron has a longer half‑life, which may allow less frequent dosing in some protocols, while ondansetron is often available in oral forms. Choice depends on clinical preference, formulation needs, and patient-specific factors.

Kytril must be stored at 2‑8 °C (refrigerated). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Proper cold‑chain management is essential to maintain product stability and efficacy.

Kytril is supplied as an injectable solution for intravenous (IV) administration. It is typically given as a single IV bolus or short infusion before the start of chemotherapy or surgery, according to the prescriber’s dosing instructions.

The most serious adverse reactions include anaphylactic or severe allergic responses, cardiac arrhythmias such as QT‑interval prolongation, and severe hypotension. Patients should be monitored for signs of these events, especially if they have pre‑existing cardiac conditions or are receiving other QT‑prolonging drugs.

Kytril is contraindicated in individuals with known hypersensitivity to Granisetron or any component of the formulation. It should also be avoided in patients with a history of prolonged QT interval or those taking other medications that significantly prolong the QT interval, unless closely monitored by a physician.